ReviewClinical pharmacokinetics2000
Pharmacokinetically guided administration of chemotherapeutic agents.
Review in Clinical pharmacokinetics, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.
- A systematic review of limited sampling strategies for platinum agents used in cancer chemotherapy.Clinical pharmacokinetics · 2007Pooled it
- Population pharmacokinetics of the BEACOPP polychemotherapy regimen in Hodgkin's lymphoma and its effect on myelotoxicity.Clinical pharmacokinetics · 2007Trial
- Population pharmacokinetics of raltitrexed in patients with advanced solid tumours.British journal of clinical pharmacology · 2004Trial
- Development and validation of limited sampling strategies for prediction of the systemic exposure to the novel anticancer agent E7070 (N-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide).British journal of clinical pharmacology · 2002Trial
- A minimal physiologically based pharmacokinetic model for high-dose methotrexate.Cancer chemotherapy and pharmacology · 2021Article
- Targeting pan-essential genes in cancer: Challenges and opportunities.Cancer cell · 2021Review
- Doxorubicin area under the curve is an important predictor of neutropenia in dogs with naturally occurring cancers.Veterinary and comparative oncology · 2019Article
- Development of a limited-sampling model for prediction of doxorubicin exposure in dogs.Veterinary and comparative oncology · 2014Article
- Article
- Effects of adjuvant chemoradiotherapy on the frequency and function of regulatory T cells in patients with head and neck cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2013Article
- The Valley of Death in anticancer drug development: a reassessment.Trends in pharmacological sciences · 2012Review
- In vitro chemosensitivity of head and neck cancer cell lines.European journal of medical research · 2010Article
- Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients.British journal of clinical pharmacology · 2006Article
- Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer.Clinical pharmacokinetics · 2006Review
- Individualised cancer chemotherapy: strategies and performance of prospective studies on therapeutic drug monitoring with dose adaptation: a review.Clinical pharmacokinetics · 2005Review
- Pharmacokinetics of high-dose chemotherapy.Bone marrow transplantation · 2004Review
- Pharmacokinetic-pharmacodynamic guided trial design in oncology.Investigational new drugs · 2003Review
- Pharmacology of anticancer drugs in the elderly population.Clinical pharmacokinetics · 2003Review
- Relationship between irreversible alopecia and exposure to cyclophosphamide, thiotepa and carboplatin (CTC) in high-dose chemotherapy.Bone marrow transplantation · 2002Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The current practice for the dose calculation of most anticancer agents is based on body surface area in m2, although lower interpatient variation in pharmacokinetic parameters has been reported with pharmacokinetically guided administration. As chemotherapeutic agents have a narrow therapeutic window, pharmacokinetically guided administration may lead to less toxicity and higher efficacy than administration on the basis of body surface area. Pharmacokinetically guided administration, using parameters such as area under the plasma concentration-time curve (AUC), steady-state plasma drug concentration and drug exposure time above a certain plasma concentration, has been studied for many antineoplastic agents. Assessment of pharmacokinetic profiles allows the characterisation of relationships between pharmacokinetic parameters and efficacy and toxicity. AUC appears to be more closely correlated with pharmacodynamics than does the dose per unit of body surface area. In particular, the AUC-guided administration of carboplatin has been extensively studied, based on the close relationship between the renal clearance of the drug and glomerular filtration rate. Several formulae and limited sampling models have been derived to predict the AUC of carboplatin. The relationship between AUC and pharmacodynamics has also been studied for other anticancer agents, for example fluorouracil, topotecan, etoposide, cisplatin and busulfan, but all less extensively than for carboplatin. The pharmacokinetically guided administration of these agents needs to be investigated further before the use of alternative administration formulae can become standard clinical practice. Prospective studies of pharmacokinetically guided versus surface area-based administration should be performed to validate pharmacokinetic-pharmacodynamic relationships and to facilitate optimal dosage of anticancer agents in the clinic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.